Can post-treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer?-Reference-Cited by-同舟云学术

Can post-treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer?

Published:2020-09-26 Issue: Volume: Page:
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int.

Author:

Goldberg Hanan¹²^ORCID,Glicksman Rachel³⁴,Woon Dixon¹,Hoffman Ally¹,Shaikh Hina¹,Chandrasekar Thenappan⁵^ORCID,Klaassen Zachary⁶⁷^ORCID,Wallis Christopher J.D.¹^ORCID,Ahmad Ardalan E.¹,Sanmamed-Salgado Noelia³⁴,Qu Xuanlu³⁴,Moraes Fabio Y.³⁴,Diamandis Eleftherios P.⁸,Berlin Alejandro³⁴⁹,Fleshner Neil E.¹

Affiliation:

1. Division of Urology; Department of Surgical Oncology; Princess Margaret Cancer Centre; University Health Network and the University of Toronto; Toronto ON Canada

2. Department of Urology; SUNY Upstate Medical University; Syracuse NY USA

3. Radiation Medicine Program; Princess Margaret Cancer Centre; University Health Network; Toronto ON Canada

4. Department of Radiation Oncology; University of Toronto; Toronto ON Canada

5. Department of Urology; Sidney Kimmel Cancer Center; Thomas Jefferson University; Philadelphia PA USA

6. Division of Urology; Department of Surgery; Medical College of Georgia; Augusta University; Augusta GA USA

7. Georgia Cancer Center; Augusta GA USA

8. Department of Pathology and Laboratory Medicine; Sinai Health System; University of Toronto; Toronto ON Canada

9. Techna Institute; University Health Network; Toronto ON Canada

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.15236/fullpdf

Reference34 articles.

1. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018

2. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911);Bolla;Lancet,2012

3. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95;Wiegel;J Clin Oncol,2009

4. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial;Thompson;JAMA,2006

5. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes;Cookson;J Urol,2007

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive value of kallikrein forms and β-microseminoprotein in blood from patients with evidence of detectable levels of PSA after radical prostatectomy;World Journal of Urology;2023-05-20

2. Clinical significance and potential molecular mechanism of miRNA-222-3p in metastatic prostate cancer;Bioengineered;2021-01-01